3M Company vs ResMed Inc. — how do they compare? 3M Company trades at $170.65 (market cap $82.99B), while ResMed Inc. trades at $197.45 (market cap $28.81B). The key difference: 3M Company is far larger — about 2.9× ResMed Inc.'s market cap, and 3M Company pays the higher dividend (1.96%). Which is the better fit depends on your goals.
| MMM | RMD | |
|---|---|---|
Market Cap | $82.99B | $28.81B |
Sector | Industrials | Health |
52-Week High | $174.61 | $293.73 |
52-Week Low | $141.10 | $182.82 |
Enterprise Value | $91.39B | $27.99B |
Dividend Yield | 1.96% | 1.21% |
Signals from Pluang's Aura AI — not financial advice
3M (MMM) surged 6.83% to $170.76 following strong Q2 2026 earnings that beat expectations, with the company raising full-year guidance. Technical indicators show a bullish trend with support at $158 and resistance at $161. Fundamentally, the company demonstrates robust profitability with 39.71% gross margins and 72.14% ROE, though revenue has declined from 2022 peaks. Recent news highlights operational improvements and growth in Safety & Industrial and Transport & Electronics segments.
The outlook is positive with earnings momentum and raised guidance, but risks include litigation liabilities and macroeconomic headwinds. Analyst consensus is mixed with 48% buy ratings but a $149.75 price target below current levels, suggesting limited near-term upside despite strong operational performance.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →